POPULARITY
19 episodes with PVR
33 episodes with PVR
10 episodes with PVR
5 episodes with PVR
5 episodes with PVR
5 episodes with PVR
3 episodes with PVR
2 episodes with PVR
3 episodes with PVR
On May 10th, Anuvab and Kunal stepped out from behind the mics and onto the stage at PVR for a hilarious live show in front of a real audience. No editing, no retakes - just pure, unfiltered chaos!It's interactive, it's unpredictable, and some of the audience stories had us wondering if we're all just collectively trauma-bonded by the same conundrums
Estimates of Postpartum Urinary Retention (PUR) incidence vary widely from 1.5% to 17.9%, with undiagnosed cases making the true incidence difficult to determine. A postvoid residual (PVR) volume of
Our very own Luke Winder, Coach and General Manager at Rise Pole Vault and recently retired elite pole vaulter, joins us on this episode of the One More Jump Podcast to share his incredible journey. From competing on the world stage at the 2022 World Championships to placing 6th at the 2024 Olympic Trials, Luke has seen it all. But his story is about more than just high heights—it's about perseverance, the mentality needed to succeed, and embracing the highs and lows of the sport. He also gives us a behind-the-scenes look at the Rise Pole Vault process and how it shaped his approach to success. This is one you don't want to miss! Thank you so much to our sponsors!!! PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action. PVR Website: https://pv-rental.web.app/ PVR Instagram: https://www.instagram.com/pvrapp/ PVR Youtube: @PVRApp Want to help support the One More Jump Podcast? Click the link below to become an episode sponsor! https://www.risepolevault.com/omj-episode-sponsorship/ Visit https://www.risepolevault.com/ for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered! RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
Dr. Cindy Chen describes her group's work on a retrospective review of association of systemic methotrexate therapy and a lower rate of proliferative vitreoretinopathy (PVR) after retinal detachment repair in large cohort of 2674 eligible patients.
In hour two, Mike & Jason talk Week 13 NFL highlights, including a big come-from-behind Seahawks win on Sunday over Aaron Rodgers' Jets, as Too Deep Zone's Mike Tanier (2:22) joins the show, plus the boys debate if it's OK to PVR sports (27:00). This podcast is produced by Andy Cole and Greg Balloch. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.
Pulmonary valve replacement following the arterial switch operation is rare. However, when necessary, how do techniques of transcatheter valve replacement fare for this indication? Why would average outcomes in this setting be less good than in the typical TPVR tetralogy of Fallot patient? How does the presence of stents in the pulmonary arteries in this patient group affect candidacy for TPVR? Are there ways to predict who might be a candidate for a TPVR vs. surgical PVR before coming to the catheterization lab? These are amongst the questions reviewed and posed to Dr. Stephen Nageotte who is the director of the cardiac catheterization laboratory at Loma Linda Children's Hospital in Loma Linda, California. DOI: 10.1002/ccd.31152
This podcast is a LONG time in the making! Chris Chappell, the Assistant General Manager of UCS Spirit, has had countless talks with Jake over the years about every aspect of pole vaulting, and we finally were able to record one! If you've ever wondered what it was about Spirit poles that was so special, then buckle up because we are getting into it on this one. Thank you so much to our sponsors!!! PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action. PVR Website: https://pv-rental.web.app/ PVR Instagram: https://www.instagram.com/pvrapp/ PVR Youtube: @PVRApp Want to help support the One More Jump Podcast? Click the link below to become an episode sponsor! https://www.risepolevault.com/omj-episode-sponsorship/ Visit https://www.risepolevault.com/ for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered! RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
Join me and Kerri as we discuss the breakthrough results dealers are experiencing with AutoFi Showroom and how dealers implementing a connected retailing sterategy are seeing higher PVR and lower staff turnover rates
Wow! Is this an episode! Scott Kendricks has one of the most unique stories as a pole vault coach that we have EVER heard. In this episode, Scott talks about his unique strategies, Sam Kendricks' legendary season, and much more! Thank you so much to our sponsors!!! PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action.PVR Website Want to help support the One More Jump Podcast? Click the link below to become an episode sponsor!https://www.risepolevault.com/omj-episode-sponsorship/ Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to get some remote instruction and guidance, risepolevault.com has got your covered! Need to buy poles? RISE Pole Vault sells all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
The 50th episode! We're celebrating this moment by answering questions that we received from our Instagram followers. Jake goes in depth on several topics including pole vault training methods, plans for RISE, the new NCAA Scholarship rules, and much more together with John Wood. Thank you so much to our sponsors!!!PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action.PVR Website Want to help support the One More Jump Podcast? Click the link below to become an episode sponsor!https://www.risepolevault.com/omj-episode-sponsorship/ Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to get some remote instruction and guidance, risepolevault.com has got your covered! Need to buy poles? RISE Pole Vault sells all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
From 'Jaane Bhi Do Yaaro', to 'Lagaan', these Hindi films should make a comeback in theatres. In this episode of 'Do I Like It', Prateek Lidhoo talks about a full proof way to get people in theatres. For some time, multiplex chain PVR has been re-releasing director retrospectives and older hit films, which is a great thing for film buffs. And it makes financial sense too. Let us know in the comment what films you want to see re-released. Learn more about your ad choices. Visit megaphone.fm/adchoices
Vincent travels to Europic 2024 in Jyväskylä, Finland to speak with Tapani Hovi and Caroline Tapparel about their careers and their research on enteroviruses and elimination of poliomyelitis. Host: Vincent Racaniello Guests: Tapani Hovi and Caroline Tapparel Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Survival of influenza virus on banknotes (Appl Environ Micro) Variant EV-A71 in immunosuppressed patient (Cell Rep) Rhinoviruses and respiratory enteroviruses (Viruses) Isolation of poliovirus in mouse cells producing Pvr (J Clin Micro) Outbreak of paralytic poliomyelitis in Finland (Lancet) Role of environmental poliovirus surveillance in global polio eradication (Epi Infect) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists Barton Blackorby, MD, and Prethy Rao, MD, MPH, about a recent peer-reviewed paper published in Ophthalmology Retina covering surgical outcomes of patients with RRD who were considered high risk for PVR and underwent either PPV alone or PPV/scleral buckling. After the break, the doctors discuss the specific mechanics of a PPV/scleral buckle that may lead to successful surgery and ask whether this paper helps us better understand risk factors for PVR.
Mitch Melnick, Jon Still and Andie Bennett started off the Thursday show talking PVR foibles, looking back on a defensive struggle in New York in Game 1 between the Panthers and the Rangers, Bobrovsky vs Shesterkin and more. Then the gang threw out their question of the day, the most stunning sports locations. Finally they wrapped up the opening hour discussing Connor McDavid's legacy heading in to the Western Conference Final between the Oilers and Stars.
Slåsskamp med busser, Carina Dahl, ønske om mer kø, sjokoladeabstinenser, forsinkelser, PVR, Logan Roy - dette stinker SnikkSnakk!Produsert av Martin Oftedal, PLAN-B Hosted on Acast. See acast.com/privacy for more information.
It has been a long time coming for this pod!!! I have wanted to sit down with Austin for a long time, because I really admire his grind and he is also a deep thinker, and I like deep thinkers. Austin has really busted through to a new level these last two years and we got to discuss what he has been doing different along with the consistent threads from the beginning that have held his vaulting together. This podcast was a great blend of technical talk and relaxed conversation about what the life of an elite pole vaulter entails. Thanks for a great chat Austin!Thank you so much to our sponsors!!!PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action.PVR WebsitePVR InstagramPVR YoutubeWant to help support the One More Jump Podcast? Click the link below to become an episode sponsor!https://www.risepolevault.com/omj-episode-sponsorship/Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered!RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
This week we go back in time to 2019 to re-review an important episode in the world of ACHD and review a registry study assessing outcomes in adults with ASD and elevated PVR who underwent ASD closure. Who was a good candidate for this approach? What were the long term outcomes of this form of therapy? Did ASD closure in this setting confer a survival benefit? We review these and many other questions in a 'virtual roundtable' discussion with Drs. Elisa Bradley, presently of Penn State and Ali Zaidi of Mount Sinai - NYC. Both are world authorities on ACHD and it is a great treat to have such 2 experts both on the show to discuss the subtleties of this complex topic.doi: 10.1016/j.ijcard.2019.03.056
In the latest Millionaire Car Salesman Podcast, Sean V. Bradley engages in a dynamic conversation with Dennis Gingrich, Sales and Finance Director at The Niello Auto Group! This high-energy episode offers a deep dive into the highline automotive market, exploring Dennis's journey from early car sales to his current leadership role. The duo discusses the challenges of the industry, emphasizing the crucial shift from transactional to relationship-based sales, especially in the evolving landscape post-pandemic! Dennis shares insights into the luxury brands represented by The Niello Auto Group, such as Porsche, Jaguar, and BMW, underscoring the significance of exceptional customer service in catering to high-end clientele. The conversation seamlessly transitions to the central theme of Customer Relationship Management (CRM), where Dennis advocates for harnessing CRM tools to their fullest potential. He stresses the pivotal role of CRM in managing relationships, tracking communication, and delivering top-tier customer service! The dialogue expands to the integration of Artificial Intelligence (AI) into CRM, shedding light on the transformative impact of AI tools in automating tasks and enhancing customer interactions! Dennis encourages sales professionals to embrace AI, recognizing its potential to elevate efficiency and effectiveness in their roles! The episode concludes with a forward-looking perspective on the impending changes in the industry, particularly the introduction of the CARS rule by the Federal Trade Commission. Dennis emphasizes the proactive use of CRM in navigating these changes and ensuring compliance. Overall, this podcast episode is a goldmine of insights for automotive professionals, offering practical tips on CRM optimization, embracing AI, and navigating the complexities of the luxury automotive market. With Dennis Gingrich's wealth of experience, listeners gain actionable strategies to thrive in the ever-evolving automotive landscape!
Two of the brightest, and most promising stars in elite pole vaulting, Bridget Williams and Julia Fixsen, offer the OMJ listeners an interview jam packed with tips, tricks, and incredible stories of their path to a NCAA National Championship and Pan American Gold, respectively. These ladies are so well spoken and an absolute blast to talk with. We could have continued talking all day about the trials and triumphs of their pole vaulting careers thus far! Thank you Julia and Bridget for such an amazing conversation!Thank you so much to our sponsors!!!PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action.PVR WebsitePVR InstagramPVR YoutubeWant to help support the One More Jump Podcast? Click the link below to become an episode sponsor!https://www.risepolevault.com/omj-episode-sponsorship/Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered!RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
The boys all sat down and discussed what a great year 2023 was at RISE Pole Vault, did a bunch of goofing around, and thought about what things 2024 may bring.Thank you so much to our sponsors!!!PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action.PVR WebsitePVR InstagramPVR YoutubeWant to help support the One More Jump Podcast? Click the link below to become an episode sponsor!https://www.risepolevault.com/omj-episode-sponsorship/Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered!RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
The Medical Research Council (MRC) Development Pathway Funding Scheme (DPFS) has announced an award of £1.2 million funding for clinical research by Moorfields Eye Hospital and the Comprehensive Clinical Trials Unit (CCTU) at UCL. The study is being led by Mahi Muqit, consultant vitreoretinal surgeon at Moorfields Eye Hospital and honorary clinical lecturer at UCL. The study is an early phase drug discovery that will explore a novel treatment for retinal detachment surgery complicated by scar tissue known as Proliferative Vitreoretinopathy (PVR). This novel use of a well-established drug has the potential to reduce or eliminate the retinal scarring from PVR and reduce sight loss. RNIB Connect Radio's Toby Davey caught up with Mahi Muqit to find out more about this new retinal detachment clinical trial and began by asking Mahi to explain what actually is a detached retina and how the detachment affects people's vision. Mahi went on to outline how the drug used in the new trial will help to reduce retina scarring which will in tern help to reduce some patients vision loss. The retinal detachment clinical trial is due to be set up late 2024 with details being signed posted on the Biomedical Research Centre pages of the Moorfields website with the hope of the study starting in January 2025. More details about Moorfields Eye Hospital can be found on their website - https://www.moorfields.nhs.uk Image: RNIB Connect Radio Bright Green 20th Anniversary Logo
How cool is it that we had 2016 Gold Medalist Katarina Stefanidi and her husband/coach Mitch Kreir for an IN PERSON podcast?!?! What an honor. This episode is packed full of amazing stories and tips from Katarina's fascinating career. If you think that she waltzed her way to that Olympic Gold Medal, you are mistaken! She has maneuvered so many obstacles and grinded for every bit of her success, and you get to hear all about it in the episode of the One More Jump Podcast.MAGIC MIND: Today's episode is brought to you by Magic Mind! Click the link below for a discount on the game changing productivity supplement I use everyday
IoT is hardware plus software, but many people still develop it as if it was hardware. Semir Haddad from MicroEJ joins Ryan Chacon on the IoT For All Podcast to discuss software-defined IoT. They talk about the benefits of a software-defined approach, green software, performance trade-offs, and sustainable design principles. Semir Haddad is the Chief Product and Strategy Officer at MicroEJ. Semir has over 20 years of experience working with industry leaders and startups, bringing innovative technologies to industrial and consumer markets. Early in his career, he worked on digital video and audio, creating the first DVD player, and developing one of the earliest PVR software solutions for which he received four patents. At STMicro and Renesas, he drove the creation of award winning lines of microcontrollers and microprocessors, including the STM32, RX, and RZ. Recently, Semir was part of the innovators at Eta Compute that created one of the first TinyML implementations. MicroEJ is a software vendor of cost-driven solutions for embedded and IoT devices. With MicroEJ solutions, smart device manufacturers transform electronic products from single-purpose to software-defined, increasing scalability, flexibility, and extensibility. Their flagship product, MICROEJ VEE, is an optimized standard software container used in millions of consumer and IoT products, such as smart home devices, home appliances, wearables, medical devices, smart meters, and industrial devices. Discover more about IoT at https://www.iotforall.com More about MicroEJ: https://www.microej.com (00:00) Intro (00:12) Semir Haddad and MicroEJ (02:13) What is software-defined IoT? (04:55) How do other IoT components fit in? (06:37) Benefits of a software-defined approach (09:05) What is green software? (13:46) Sustainable design performance trade-offs (14:55) What are sustainable design principles? (17:08) Learn more and follow up SUBSCRIBE TO THE CHANNEL: https://bit.ly/2NlcEwm Join Our Newsletter: https://www.iotforall.com/iot-newsletter Follow Us on Social: https://linktr.ee/iot4all Check out the IoT For All Media Network: https://www.iotforall.com/podcast-overview
Seasoned and vibrant professional with almost 14 years of experience in the communication sector, Neha Bajaj, founded Scroll Mantra in 2014 with a vision to provide a holistic marketing strategy for upcoming and established brands. She graduated from Delhi University in Bachelor of Commerce and worked for almost eight years before taking the plunge to start her own agency. She started her career with an MNC in Delhi where she had a long stint of six years. Post that, she moved to head the northern region for a Bangalore based PR agency for two years. She has strong inclination towards achieving operational excellence, media intelligence, and designing strategic campaigns for brands to realize communication objectives. She has worked with many leading brands like PVR, Airbus, AITA, Huawei, Bentley, Lamborghini, Bugatti, Myntra.com, Jabong.com, Zivame.com, LAP, DKNY, MINISO, Marks & Spencer, Carlton London, ViewSonic, HCL, ASICS, Sunglass Hut, DKNY, Claire's, Mothercare, Allen Solly, Van Heusen, Louis Phillippe, bluO, W for Woman, AHS, Asian Roots Spa, Sportsfit and more. Her areas of focus include designing creative brand campaigns, team leadership, counselling and mentorship to deliver desired results. In her career of 14 years she has headed marketing communications for national and global companies and has a strong expertise in sectors across Entertainment, Consumer Lifestyle, Legal, Infrastructure, FMCG, Hospitality, F&B, Personalities, Corporate and Finance. She always strives for new opportunities to achieve a high standard in whatever is undertaken and has successfully built a complete marketing communication agency catering to verticals like Public Relations, Digital Media Marketing, and Social Media Marketing apart from Graphic Designing and Corporate Branding.
Recent Michigan State grad and 2023 Big Ten Champion, Trevor Stephenson joins the podcast at his new place of employment, RISE Pole Vault. This was a great conversation for both Trevor and I because we have really just met, and I was able to learn so much about his story, and what makes him tick. He is very insightful and just an all around good dude. I am so grateful to coach him as a RISE Elite Vaulter and we love having him as a member of the RISE Fam. Thanks T-Bird!!!PVR App - The future of pole rentals: If you are in the business of renting pole vaulting poles, you need to see what PVR can do for you! Check out the links below for more info and to see PVR in action.PVR WebsitePVR InstagramPVR YoutubeWant to help support the One More Jump Podcast? Click the link below to become an episode sponsor!https://www.risepolevault.com/omj-episode-sponsorship/Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered!RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
This week we delve into the world of ACHD when we review a recent important work from the multicenter INDICATOR study group assessing the impact on overall outcomes in TOF patients who have their pulmonary valve replaced. Are survival rates improved by replacement of the pulmonary valve in the TOF patient? What about the effect on ventricular tachycardia? What are the proposed mechanisms by which PVR can positively affect this critical outcomes? Are there differences between transcatheter PVR and surgical in this regard? Is there an RV volume that is the 'sweet spot' for PVR? These are amongst the many questions posed to Professor of Pediatrics and Medicine at Harvard University, Dr. Anne Marie Valente. https://doi.org/10.1016/j.jacc.2023.02.052
Welcome to "PICU Doc On Call," a podcast dedicated to current and aspiring intensivists. In this episode, Dr. Pradip Kamat and Dr. Rahul Damania discuss an interesting case of a 16-year-old male with high-grade fever and abdominal pain. The patient also presents with a rash and other concerning symptoms, leading to urgent medical attention. They provide a summary of the key elements from the case, including vital signs, physical examination findings, and laboratory and imaging results.Dr. Kamat then shares his thought process regarding the working diagnosis for this patient, considering several possibilities such as severe bacterial infection, atypical appendicitis or cholecystitis, toxic shock syndrome, and systemic inflammatory processes like Multisystem Inflammatory Syndrome in Children (MIS-C) and atypical Kawasaki disease.Moving on to the topic of vasopressors, Dr. Damania explains the importance of understanding how these medications work and their specific pharmacological properties. They discuss the classification of shock as cold or warm and the limitations of relying solely on clinical signs to categorize septic shock in children.They highlight the challenges in selecting the appropriate vasopressor, such as a lack of standardization in clinical examination and individual variability in response to medications. They emphasize the need for a comprehensive approach when evaluating and managing pediatric shock patients, considering multiple factors beyond traditional bedside signs.The hosts then engage in a rapid review of pressors, starting with a multiple-choice question regarding the choice of vasoactive infusion for a patient with toxic shock syndrome. They discuss the pros and cons of using norepinephrine (NE) in distributive shock and highlight its vasoconstrictive effects, inotropic activity, and potential side effects.They proceed to compare NE with epinephrine, explaining the differences in their actions on adrenergic receptors and their effects on various circulations. They mention that epinephrine acts on all adrenergic receptors and has hemodynamic and metabolic effects, redirecting cardiac output and increasing myocardial oxygen demand.Lastly, the hosts touch on phenylephrine, a vasopressor that acts on the alpha-1 receptor and elevates systemic vascular resistance (SVR) and pulmonary vascular resistance (PVR). They stress the importance of securing central line access when administering vasopressors to avoid harm to peripheral and systemic tissues.In conclusion, this episode provides valuable insights into the diagnosis and management of a complex pediatric case involving high-grade fever, abdominal pain, and shock. The hosts also offer a rapid review of common vasopressors, highlighting their mechanisms of action, pros, and cons.
In this week's episode from SCAI 2023, we speak with Professor Kritvikrom Durongpisitikul of Mahidol University, Siriraj Hospital in Bangkok, Thailand about their experience in transcatheter and surgical pulmonary valve replacement (PVR). Who is a candidate for each in the present era? Why was surgery associated with higher mortality rates in this work? Should the criteria for transcatheter PVR differ in comparison with surgery? Dr. Durongpisitikul shares his insights in this live session from SCAI which is co-moderated by Dr. Aimee Armstrong of Children's Nationwide Hospital. https://doi.org/10.1016/j.jscai.2022.100408
Dr. Jason Hsu from Wills Eye Hospital returns to The Retina Channel to discuss his groups' retrospective study of eyes with advanced retinal detachement (PVR grade C or worse) that underwent retinectomy without lensectomy. Their study showed that 75% of these eyes at 3 months (and 68% at 6 months) had single surgery anatomic success. The study is suggestive that lensectomy and even peripheral vitreous base sheving may not be necessary when doing retinectomy for advanced RD cases. Full reference to the article: Mahmoudzadeh R, Mokhashi N, Anderson H, Patel S, Salabati M, Chiang A, Kuriyan AE, Gupta OP, Mehta S, Garg SJ, Hsu J. Outcomes of Retinectomy without Lensectomy in Rhegmatogenous Retinal Detachments with Proliferative Vitreoretinopathy. Ophthalmol Retina. 2023 Jan;7(1):52-58. doi: 10.1016/j.oret.2022.07.008. Epub 2022 Aug 5. PMID: 35940476.
Happy three year anniversary!!! Thank you so much to everyone who has supported us over the last three years. It is truly humbling to see how far this has come, and we are so incredibly grateful. To celebrate, we gathered some questions from fans and did a little Q and A. This was our first time doing an internal podcast and we hope you enjoy it. One more time....THANK YOU FOR LISTENING TO OMJ!!!Today's Episode is brought to you by PVR. Discover how the PVR app is revolutionizing the pole vault rental experience today. Want more info? Click this LINK, fill out the form, and we will send you a features guide! Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered!RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
Fresh off their gold medal performance at the World Mixed Doubles Championships in Korea, Korey Dropkin and Cory Thiesse join the guys (4:30) to talk about how they were able to pull off such a great performance (8:10), their philosophy behind the game, how they became a team and how their careers have always paralleled each other, the use of the power play in mixed doubles, how they intend to balance four-person curling with mixed doubles, and they give their thoughts on the mixed doubles schedule.The guys answer a question about how PVR affects the way people watch games and also offer a couple of ideas on shortening broadcasts (24:30). We get an update on the Mixed Doubles and the Sr's World Championships on What's Happening Around the Curling World (31:30), Kevin gives a preview of the Champions Cup (39:00) and the guys give their predictions for the tournament (42:00).In Hot Rock Topics, Kevin and Warren bring up some ideas on how they can speed up the game in the future (45:00).This podcast is produced by Warren Hansen & Kevin Martin, recorded and mixed by Mike Rogerson, and hosted by Kevin Martin, Warren Hansen and Jim Jerome.Contact the podcast -- insidecurling@gmail.comThe views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.
Rode has released a number of new products at the National Association of Broadcasters Show in Las Vegas, DJI – as we predicted – has released the stunning Inspire 3, MG releases another affordable EV, we take a look at the ASUS Zenbook foldable laptop, the device from Morphee that can manage your anxiety and mental health, Fetch has had a major software update of it popular PVR and we'll answer all your questions in the Tech Guide Help Desk. Learn more about your ad choices. Visit megaphone.fm/adchoices
CardioNerds join Dr. Samid Muhammad Farooqui, Dr. Hiba Hammad, and Dr. Syed Talal Hussain, from the University of Oklahoma Pulmonary and Critical Care Medicine Fellowship Program, in Oklahoma City. The fellows will take us in a fascinating discussion of a case of rapidly progressing dyspnea and pulmonary hypertension in a patient with metastatic breast cancer. They will then reveal an interesting etiology of pulmonary hypertension, where the secret was on the wedge! University of Oklahoma faculty and expert in pulmonary hypertension and right ventricular physiology, Dr. Roberto J. Bernardo provides the E-CPR for this episode. Audio editing by CardioNerds Academy Intern, Dr. Christian Faaborg-Andersen. A septuagenarian female, with a past medical history of metastatic breast adenocarcinoma, presented to the hospital with worsening dyspnea over a period of 3 weeks. She was found to be in rapidly progressive hypoxic respiratory failure with unremarkable chest x-ray, CTA chest, and V/Q scan. Transthoracic echocardiogram revealed elevated RVSP and a subsequent right heart catheterization showed pre-capillary pulmonary hypertension with a low cardiac index. She was treated for rapidly progressive RV dysfunction with inotropic support and inhaled pulmonary vasodilators until she decided to pursue comfort measures. Wedge cytology came back positive for malignant cells, confirming a diagnosis of Pulmonary Tumoral Thrombotic Microangiopathy (PTTM). CardioNerds is collaborating with Radcliffe Cardiology and US Cardiology Review journal (USC) for a ‘call for cases', with the intention to co-publish high impact cardiovascular case reports, subject to double-blind peer review. Case Reports that are accepted in USC journal and published as the version of record (VOR), will also be indexed in Scopus and the Directory of Open Access Journals (DOAJ). CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - When Tumors Take Your Breath Away - University of Oklahoma College of Medicine Pearls - When Tumors Take Your Breath Away - University of Oklahoma College of Medicine Pulmonary arterial hypertension (PAH) is a progressive disorder of the pulmonary vasculature, characterized by progressive obliteration and remodeling of the pulmonary circulation, resulting in increased pulmonary vascular resistance and increased right ventricular (RV) wall stress, abnormal right ventricular mechanics, and eventually RV dysfunction and death. Pulmonary hypertension (PH) is divided into pre-capillary and post-capillary profiles, where pre-capillary PH is hemodynamically characterized by a mean pulmonary artery pressure (mPAP) > 20 mmHg, pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) ≥ 3 Woods Units (WU), and post-capillary PH is defined as mPAP > 20 mmHg, PAWP ≥ 15 mmHg, and PVR can be either < 3 WU (isolated post-capillary PH) or ≥ 3 WU (combined pre- and post-capillary PH). Pulmonary arterial hypertension (PAH) falls under the pre-capillary PH profile. Dyspnea on exertion is the most common manifestation of PH, and the most common initial complain. Other symptoms and physical findings such as venous congestion, peripheral edema, signs of RV dysfunction or syncope present later in the disease course. As such, PH has to be considered in the differential diagnosis of dyspnea, especially in cases of undifferentiated or unexplained dyspnea. PAH is a chronic but progressive condition, where symptoms progress over the course of months to years. Subacute or rapidly progressive forms of PH (symptoms rapidly worsening over the course of weeks) should warrant consideration for alternative etiologies (i.e., pulmonary embolism or a different cardiopulmonary disorder as the main d...
Fresh off a HUGE 6 meter jump in route to his NCAA Indoor National Championship, Sondre Guttormsen joins the podcast to discuss his incredible indoor season and what his day to day looks like to get him going this high in the air. Him and his family are incredibly knowledgable in the pole vault and we got into topics such as the support for track and field in Europe vs. USA, overtraining, and much more. This episode of the podcast is brought to you by PVR!!! PVR is the worlds first, state of the art, pole rental app that is going to take your pole rental business to the next level. If you would like more information on how you can streamline your rentals, please fill out the form below...https://forms.gle/dAa1WFk6yeAqCjrD9Visit RISEPolevault.com for all things pole vault!!! Whether you are looking to take a vaulting class or compete in a competition at our the state of the art RISE Pole Vault Training Center located in Joliet, IL, or wanting to use one of our many services ranging from pole vault business consulting to virtual coaching in the vault, risepolevault.com has got your covered!RISE Pole Vault is now selling all three major pole brands including UCS Spirit, Essx, and Pacer. Email in to support@risepolevault.com and let us get you set up with some new poles!
In this episode of Market Minutes, Shailaja Mohapatra talks about one full year of interest rate hiking cycle by the US Federal Reserve. PVR, Rail Vikas Nigam Limited and Sunil Singhania-backed Dynamatic Technologies are some stocks to watch out for. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends.
Britton and I visit about life after divorce, the loss of our fathers and how unprocessed pain can show up. We share from our personal experiences and some of what we have learned along the way.What is the result of unprocessed pain and/or unresolved conflict? Often times it can manifest in this “tool” known as the PVR triangle. A PVR triangle is having a powerless mindset to the circumstance and, in the absence of dealing with that pain or conflict, we will show up as a persecutor victim, or seeking rescue because we don't believe there's power to change the situation. Find out more about Britton and how to get in touch with him at4014consulting.comZion61ministries.net
Join CardioNerds to learn about patent ducts arteriosus and Eisenmenger syndrome! Dr. Dan Ambinder (CardioNerds co-founder), ACHD series co-chair Dr. Dan Clark, Dr. Tony Pastor (ACHD fellow, Harvard Medical School), and Dr. Kate Wilcox, Medicine/Pediatrics Resident, Medical College of Wisconsin join Dr. Candice Silversides (Editor-in-chief #JACCAdvances) for this terrific discussion. Notes were drafted by Dr. Kate Wilcox. .Audio editing by CardioNerds Academy Intern, Dr. Maryam Barkhordarian. The CardioNerds Adult Congenital Heart Disease (ACHD) series provides a comprehensive curriculum to dive deep into the labyrinthine world of congenital heart disease with the aim of empowering every CardioNerd to help improve the lives of people living with congenital heart disease. This series is multi-institutional collaborative project made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Josh Saef, Dr. Agnes Koczo, and Dr. Dan Clark. The CardioNerds Adult Congenital Heart Disease Series is developed in collaboration with the Adult Congenital Heart Association, The CHiP Network, and Heart University. See more Disclosures: None CardioNerds Adult Congenital Heart Disease PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Patent Ductus Arteriosus & Eisenmenger Syndrome The ductus arteriosus, which is formed from the distal portion of the left sixth arch, is key to fetal circulation because it allows blood to bypass the high resistance pulmonary circuit present in utero. After birth there is a significant drop in pulmonary vascular resistance (PVR) which generally leads to functional ductal closure within 48 hours (permanent seal takes 2-3 weeks to form). Risk factors for having a PDA include birth before 37 weeks of gestation, trisomy 21, and congenital rubella. A PDA results in a left to right shunt (qP:qS >1) which over time overloads the left side of the heart and causes pulmonary vascular remodeling. The extra workload on the left side of the heart causes left atrial (can cause atrial arrhythmias) and left ventricular dilation. If left untreated you can eventually have shunt reversal due to very high PVR (Eisenmenger physiology). There are some treatment options at this point (pulmonary vasodilators, etc) but it's definitely better to close the PDA before this point. One interesting physical exam finding that can stem from shunt reversal in a hemodynamically significant PDA is differential cyanosis (upper body or pre-ductal saturations will be higher than lower body/post-ductal saturations). You can also see clubbing in the toes but not the hands for the same reason. Meet Our Collaborators! Adult Congenital Heart AssociationFounded in 1998, the Adult Congenital Heart Association is an organization begun by and dedicated to supporting individuals and families living with congenital heart disease and advancing the care and treatment available to our community. Our mission is to empower the congenital heart disease community by advancing access to resources and specialized care that improve patient-centered outcomes. Visit their website (https://www.achaheart.org/) for information on their patient advocacy efforts, educational material, and membership for patients and providers CHiP Network The CHiP network is a non-profit organization aiming to connect congenital heart professionals around the world. Visit their website (thechipnetwork.org) and become a member to access free high-quality educational material, upcoming news and events, and the fantastic monthly Journal Watch, keeping you up to date with congenital scientific releases. Visit their website (https://thechipnetwork.org/) for more information.
PVR, the country's largest multiplex chain, made up for the pandemic-induced revenue loss by raising the prices of tickets and food and beverages.But it saw its occupancy fall to the lowest levels in a decade even after movie theatres reopened at full capacity.What is keeping India's theatres empty?Tune in to find out.
What Is A Barf Bowl? | Knight Helmet AC/DC | DUGY Collects Steam | OttaWHAT? | Instant Answer Question Time | Be The Least Boring | Anonytext | DUGY Don't PVR
Many of the current-day operational shifts in retail automotive are driven by consumers' ever-evolving expectations and habits. Therefore, it is essential to 'future-proof' your dealership by putting processes in place now. As a result of A2Z Sync's one-person sales methodology, retailers have been able to expand their businesses. In this episode of the David Spisak Show, we will discuss the one-person sales concept and how it influences the customer experience.As the world adjusts to a new standard, many businesses are having trouble balancing online and in-person encounters, so please join us in welcoming Natalia Giner, CEO of A2Z Sync. The customer service process has been a minefield for auto dealerships.Natalia has worked in the automobile industry for over 20 years. She has brought her expertise to A2Z Sync to provide customers with a revolutionary experience, primarily focusing on developing innovative, client-centric services. She has been in charge of the A2Z platform's development team for the past three years, during which numerous dealers have successfully converted to the One-Person Sales Model. With a background in product development and business consulting, she is well-suited to her role of advising dealers on adapting to the automobile industry's changing face.A2Z Sync set out to transform the traditional retail industry. A2Z Sync provides operational readiness evaluations, extensive in-dealership training, and continuing technical and training assistance to aid its clients in making the switch to a One-Person Sales Model. To ensure the continued success of its software platform, A2Z Sync creates a bespoke implementation plan for each dealer.Key TakeawaysThe modern automobile customer is impatient for service, wants answers immediately, and values convenience. Thanks to this revolutionary software, a single salesperson can handle the vast majority of a transaction by themselves.Consistent and unified service throughout the journey is crucial to ensuring your dealership and staff offer the most outstanding digital client experience. We will show you how to take these services beyond your dealership's doors while still catering to your customers' needs.Reduced transaction times, greater PVR, more satisfied customers, and lower employee turnover are just some of the benefits one-person sales models provide to dealers. Since they deal with clients one-to-one, they can establish deeper bonds of trust and loyalty. Every salesman has their own system, and it might be anything from one car per month to ten vehicles every month, but Without a clearly defined process, there are likely a hundred different ways of doing things. Many people throw up their hands in frustration when faced with the procedure. However, there is a reason why FedEx and Amazon both adhere to such strict guidelines; these two companies have a secret weapon: a well-defined method.However, from the client's perspective, transparency is also desired. They desire shared authority over a process. But if you don't have a strategy, how can you offer them joint jurisdiction over it? And thus, Not only is it beneficial to the dealer only, but it also benefits the customer because they can do things the way they want.But how can we tell if we are winning or losing if we don't examine the process and identify areas for improvement?Find out how to set your dealership apart by providing a more personalized and exciting experience.Visit https://linktr.ee/spisakd for all our linksUpdates here: https://www.facebook.com/groups/davidspisakscommunity/ Like this show? Please leave us a rating and review where you're listening right now!
Many of the current-day operational shifts in retail automotive are driven by consumers' ever-evolving expectations and habits. Therefore, it is essential to 'future-proof' your dealership by putting processes in place now. As a result of A2Z Sync's one-person sales methodology, retailers have been able to expand their businesses. In this episode of the David Spisak Show, we will discuss the one-person sales concept and how it influences the customer experience. As the world adjusts to a new standard, many businesses are having trouble balancing online and in-person encounters, so please join us in welcoming Natalia Giner, CEO of A2Z Sync. The customer service process has been a minefield for auto dealerships. Natalia has worked in the automobile industry for over 20 years. She has brought her expertise to A2Z Sync to provide customers with a revolutionary experience, primarily focusing on developing innovative, client-centric services. She has been in charge of the A2Z platform's development team for the past three years, during which numerous dealers have successfully converted to the One-Person Sales Model. With a background in product development and business consulting, she is well-suited to her role of advising dealers on adapting to the automobile industry's changing face. A2Z Sync set out to transform the traditional retail industry. A2Z Sync provides operational readiness evaluations, extensive in-dealership training, and continuing technical and training assistance to aid its clients in making the switch to a One-Person Sales Model. To ensure the continued success of its software platform, A2Z Sync creates a bespoke implementation plan for each dealer. Key Takeaways The modern automobile customer is impatient for service, wants answers immediately, and values convenience. Thanks to this revolutionary software, a single salesperson can handle the vast majority of a transaction by themselves. Consistent and unified service throughout the journey is crucial to ensuring your dealership and staff offer the most outstanding digital client experience. We will show you how to take these services beyond your dealership's doors while still catering to your customers' needs. Reduced transaction times, greater PVR, more satisfied customers, and lower employee turnover are just some of the benefits one-person sales models provide to dealers. Since they deal with clients one-to-one, they can establish deeper bonds of trust and loyalty. Every salesman has their own system, and it might be anything from one car per month to ten vehicles every month, but Without a clearly defined process, there are likely a hundred different ways of doing things. Many people throw up their hands in frustration when faced with the procedure. However, there is a reason why FedEx and Amazon both adhere to such strict guidelines; these two companies have a secret weapon: a well-defined method. However, from the client's perspective, transparency is also desired. They desire shared authority over a process. But if you don't have a strategy, how can you offer them joint jurisdiction over it? And thus, Not only is it beneficial to the dealer only, but it also benefits the customer because they can do things the way they want. But how can we tell if we are winning or losing if we don't examine the process and identify areas for improvement? Find out how to set your dealership apart by providing a more personalized and exciting experience. Visit https://linktr.ee/spisakd for all our links Updates here: https://www.facebook.com/groups/davidspisakscommunity/ Like this show? Please leave us a rating and review where you're listening right now!
This week we delve into the world of bovine jugular vein grafts for the treatment of pulmonary valve dysfunction and the possible enhanced risk for infective endocarditis. How commonly are these valves affected by endocarditis and does placement at surgery in comparison to the cath lab confer a lower risk for this dreaded complication? What factor was most highly associated with the risk for endocarditis with a bovine jugular valve vein graft for PVR? A description from the team at Cincinnati Children's Hospital is on tap this week! https://doi.org/10.1177/21501351211065363
On this week's episode of The Boxoffice Podcast, Rebecca Pahle and Jesse Rifkin discuss a photo-finish for the top spot at the box office between Warner Bros.' Elvis and Paramount's Top Gun: Maverick. In our final dispatch from CineEurope, Daniel Loria is joined by Celluloid Junkie's Sperling Reich to cover the convention's main themes and trends. And in the feature segment, Daniel is joined by Guillaume Thomine Desmazures of ICE Theaters and Renaud Palliere, CEO of India's PVR Cinemas-The Luxury Collection, to chat about the Indian exhibitor's approach to premium formats. Give us your feedback on our podcast by accessing this survey: https://forms.gle/CcuvaXCEpgPLQ6d18 Episode Resources: Showbiz Sandbox Podcast ICE Theaters Apex Order Pickup Solutions ICE Theaters Announces Launch in India with PVR Cinemas Partnership What to Listen For 00:00 Intro 02:01 Paramount and Warner Bros. released studio estimates for Top Gun: Maverick and Elvis 06:26 Box office top 5 11:01 Premiumization of cinemas 15:58 Marketing of higher ticket prices 23:08 Now, it's selling tickets to your theater 26:09 PVR Cinemas signing a deal with ICE Theaters 27:07 The PVR network of theaters in India 29:42 Diversification of premium formats 31:24 ICE Theater format combined with Bollywood content
The Automotive Troublemaker w/ Paul J Daly and Kyle Mountsier
We're making some big trouble on a Monday morning as we talk through Volvo's partnership with the creator of the popular game Fortnite, Epic Games. We also have special guest, Brain Pasch on the show to talk about his direct approach to questioning Ford CEO, Jim Farley's direct approach to selling EVs.Fortnite creator, Epic Games, partners with Volvo to unleash in car experience(Side note)If you have kids that play the game, you know that Chap 3 Season 3 went down over the weekend in a giant mech battleIn a statement Thomas Stovicek, Volvo head of user experience, said that he hopes the partnership will: provide "richer layers of information" to the driver without the "additional distraction or stress" “About bringing astonishing game-quality graphics into our cars”"provide entirely new functions and services" such as improved connectivity with other vehicles and the outside environment”Will run on the Volvo ‘HMI' (Human machine interface)Take away: This is a a great example of importing the best thinking and tools from outside the industryAn Open Letter to Jim Farley w/ Guest Brian PaschOn Friday, June 3rd, Industry advocate and fellow troublemaker Brian Pasch released an open letter to Ford CEO, Jim Farley challenging several statements made in a recent talk and asking 10 follow up questions on behalf of franchised retail Auto DealersIs Ford changing their building standards and facility requirements today to minimize the investments dealers need to make for new facilities or facility upgrades?Who is going to work out these deals and trade values on a national Ford EV sales portal when no technology platform can do it today?In your consumer-direct model, where Ford sets an online trade-in value, who is purchasing the vehicle and where does it go?Will Ford be selling certified pre-owned EV models direct to consumers on your national portal?What is your risk tolerance when other OEMs have local dealer lots filled with ready-to-buy competing models and you start to lose market share? What happens when Ford models (and likely incentives) do not sell through national inventory that you pre-built or orders fail to meet your production goals?Will local dealers have the ability to offer their own financing and F&I products, or will Ford control those offerings?Are you willing to share what the PVR in your model looks like compared to what dealers are realizing today?Could the complexity of trims and optional packages in the Ford EV lineup challenge consumers' ability to confidently configure, build, and purchase a vehicle online?Which technology company has been chosen to design and build your national sales portal?Get the Daily Push Back email at https://www.asotu.com/Listen to other episodes: https://www.asotu.com/media/podcastsRead our most recent email at: https://www.asotu.com/media/push-back-emailShare your positive dealer stories: https://www.asotu.com/positivityInsta: https://www.instagram.com/automotivestateoftheunion/ Twitter: https://twitter.com/asotu_ Tik Tok: https://www.tiktok.com/@ASOTU FB: https://www.facebook.com/automotivestateoftheunion
This week, please join author Sanjiv Shah, Editorialist Evangelos Michelakis, and Associate Editor Justin Ezekowitz as they discuss the article "Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure" and Editorial "Atrial Shunt Devices in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction and the Pulmonary Circulation: Promises and Concerns." Dr. Carolyn Lam: Welcome to Circulation On The Run, your weekly podcast summary and backstage pass to the Journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from The National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health, in Richmond, Virginia. Dr. Carolyn Lam: Greg, I love today's featured article. It's all about heart failure with mildly reduced and preserved ejection fraction, talking about device therapy and the response to therapeutic atrial shunt device. Now, this is a very interesting discussion of how specifically selecting patients based on latent pulmonary vascular disease may hold some answers, but we're going to keep everyone hanging here. You've got to, got to listen to the discussion. But first, we'd like to tell you about some of the papers in today's issue. And I think Greg, you've got one to start us with, right? Dr. Greg Hundley: Absolutely. Carolyn, thank you so much. Well, this first paper comes from Dr. Eliot Peyster from the University of Pennsylvania. And Carolyn, the aim of this study was to leverage computational methods for analyzing digital pathology images from routine endomyocardial biopsies, to develop a precision medicine tool for predicting cardiac allograft vasculopathy, years before overt clinical presentation. Dr. Carolyn Lam: Ooh, interesting. Again, precision tools. So what did they find? Dr. Greg Hundley: Right, Carolyn. So there was a clinical predictive model that achieved modest performance on the independent test set, with area under the receiver operating curve of 0.7. But interestingly, a histopath- predictive model for predicting cardiac allograft rejection achieved good performance, with an area under the receiver operating curve of 0.8. Most importantly, however, a model, incorporating both clinical and histopathologic features, achieved excellent predictive performance, with an area under the receiver operating curve of 0.93. Dr. Greg Hundley: So in summary, Carolyn, these authors found that prediction of future cardiac allograft vasculopathy development is greatly improved by incorporation of computationally extracted histologic features. Their results suggest morphologic details, contained within regularly obtained biopsy tissue, have the potential to enhance precision and personalization of treatment plans for post heart transplant patients. Dr. Carolyn Lam: Aw, that's cool. Makes so much sense, but yet so novel. Thanks. Dr. Carolyn Lam: Well, for the paper I want to talk about, we are going to talk about dapagliflozin. Now we know the SGLT-2 inhibitor, dapagliflozin, improved heart failure and kidney outcomes in patients with Type two diabetes with or at high risk for cardiovascular disease, in the DECLARE–TIMI 58 trial. In the current paper, authors, led by Dr. Wiviott from the TIMI study group, aimed to analyze the efficacy and safety of dapagliflozin stratified, according to baseline systolic blood pressure. Dr. Greg Hundley: Ah, so an interesting question, since SGLT-2 inhibitors are known to reduce blood pressure. And given the concerns regarding the safety of SGLT-2 inhibitors, in patients with low to normal systolic blood pressure. So Carolyn, what did they find? Dr. Carolyn Lam: Nicely put Greg. So in patients with type two diabetes with, or at high risk of, atherosclerotic cardiovascular disease, dapagliflozin reduced the risk for heart failure hospitalizations and renal outcomes, regardless of baseline systolic blood pressure, with no difference in benefit for reduction in heart failure or renal outcomes, among patients with blood pressure from the normal range, all the way to severe hypertension. Moreover, there appeared to be no difference in adverse events of volume depletion, acute kidney injury, or amputations, across the levels of baseline blood pressure. So these results indicate that dapagliflozin provides important cardiorenal benefits in patients with Type two diabetes at high risk, the independent of baseline blood pressure. Dr. Greg Hundley: Oh, very nice, Carolyn. Well, my next paper comes to us from the world of preclinical science, and it's from professor Jeffrey Towbin and colleagues, at Le Bonheur Children's Hospital. So Carolyn, as we know, arrhythmogenic cardiomyopathy is an inherited genetic disorder of desmosomal dysfunction, and plakophilin-2 has been reported to be the most common disease causing gene when mutation is positive. Now in the early concealed phase, the arrhythmogenic cardiomyopathy heart is at high risk of sudden cardiac death before cardiac remodeling occurs, due to mis-targeted ion channels and altered calcium handling. However, the results of pathogenic plakophilin-2 variants on myocyte contraction in arrhythmogenic cardiomyopathy pathogenesis, really remains unknown. So Carolyn, these authors studied the outcomes of a human truncating variant of plakophilin-2 on myocyte contraction, using a novel knock-in mouse model, as well as evaluation of human subjects. Dr. Carolyn Lam: Oh, interesting. So what were the results from this plakophilin-2 knock-in mouse model? Dr. Greg Hundley: Right, Carolyn. So serial echocardiography, a plakophilin-2 heterozygous mice revealed progressive failure of the right ventricle, but not the left ventricle, in animals older than three months of age. Now next, adrenergic stimulation enhanced the susceptibility of plakophilin-2 heterozygous hearts to tachyarrhythmia and sudden cardiac death. Contractility assessment of isolated myocytes demonstrated progressively reduced plakophilin-2 heterozygous RV cardiomyocyte function, consistent with right ventricular failure, measured by echocardiography. Dr. Greg Hundley: And the next, Western blotting of plakophilin-2 right ventricular homogenates revealed a 40% decrease in actin. In contrast, plakophilin-2 heterozygous left ventricular myocytes had normal contraction and actin expression. Dr. Greg Hundley: And finally, Carolyn, Western blotting of cardiac biopsies revealed actin expression was 40% decreased in the right ventricles of end stage arrhythmogenic cardiomyopathy patients. So in conclusion, Carolyn, during the early concealed phase of arrhythmogenic cardiomyopathy, reduced actin expression drives loss of RV myocyte contraction, and that contributes to progressive RV dysfunction. Dr. Carolyn Lam: Wow. Thanks, Greg. Well, also in today's issue, there's an exchange of letters among Drs. Whitman, Ibrahim, and Løfgren, regarding physics at the heart of the matter, referring to the article, “Anterior–Lateral Versus Anterior–Posterior Electrode Position for Cardioverting Atrial Fibrillation.” Dr. Greg Hundley: Right Carolyn. And also in the mail bag, there's an On My Mind piece, from Professor Taegtmeyer, entitled, “The 2022 Beijing Winter Olympics, The Spotlight On Cardiac Metabolism.” Dr. Greg Hundley: Well, how about we get onto that feature article, and learn a little bit more about atrial shunts, and how they may be helpful in heart failure with preserved ejection fraction? Dr. Carolyn Lam: Ooh, can't wait. Dr. Greg Hundley: Well, listeners, we have a very interesting feature discussion today related to hemodynamics pertaining to interatrial shunt devices, in those with and without pulmonary hypertension. And we have, gosh, a repertoire of speakers today. We have Dr. Sanjiv Shah, from Northwestern University in Chicago, Dr. Evangelos Michelakis, from Edmonton Alberta, and our own associate editor, Dr. Justin Ezekowitz, also from Edmonton Alberta. Dr. Greg Hundley: Well, Sanjiv, we're going to start with you. Describe for us, some of the background pertaining to your study, and what was the hypothesis that you wanted to address? Dr. Sanjiv Shah: Great. Thanks, Greg. Thanks for having me today. Well, the background of our study is that, it was a subgroup analysis, or a secondary analysis, of the REDUCE LAP-HF II trial. Now this trial has been in the making for over 12 years, almost 13 years. It started out as an idea that was David Celermajer. David is a pediatric cardiologist in Australia, who had this idea that, in mitral stenosis patients, it's well known that, if there's a concomitant secundum ASD, a congenital secundum ASD, in these patients with mitral stenosis do better. They have a way to unload the left atrium, and distribute that blood to the systemic veins and the right atrium, the right side of the heart. And so could this be helpful in quote, diastolic, heart failure or HFpEF? Dr. Sanjiv Shah: And so, I started working with him about 12 years ago. This started out as a concept. It was studied in animal models, and then in humans, in open label studies, and then, in a first randomized controlled trial. Where we showed, that an intraatrial shunt device, an iatrogenic ASD, so to speak, put in humans with heart failure with risk preserved EF, results in a lowering of exercise pulmonary capillary wedge pressure. And so based on that data, we designed a pivotal trial, a Phase III trial, the largest trial of its kind, of heart failure with preserved and mildly reduced ejection fraction, to see if interatrial shunt device would improve outcomes. And we published that trial earlier this year in the Lancet. Unfortunately, it was a totally neutral trial. And when you have a neutral trial in any condition, but as we see often in HFpEF, the question is, was it neutral overall? Or was there a subgroup that benefited? And what we found in that trial was that, there were three predefined subgroups that came out that seemed like there was a difference. Dr. Sanjiv Shah: First, there was a sex difference. Women did better. Men did worse with the device. Then, there was right atrial volume. Those with bigger right atrial volumes did worse. If you had a smaller right atrial volume, you did better. But the most significant interaction and subgroup was exercise pulmonary artery systolic pressure. Dr. Sanjiv Shah: If the pulmonary artery systolic pressure was greater than 70 at 20 Watts of exercise, so just with a little bit of exercise, those patients did worse. And if PA pressure stayed low, the patients did better. And so we sought to further explore this to say, "Okay, what's exactly going on?" In a post hoc analysis, what's going on with the pulmonary vasculature during exercise, and how does that differentiate how patients potentially respond to the device? And that's what we hope to figure out. Dr. Sanjiv Shah: We hypothesize, that if exercise pulmonary vasculature resistance is lower, then the shunt can actually work, and blood can flow from the left to the right, into the lungs, and the right heart doesn't get too overloaded. And we know, that the normal response of the pulmonary vasculature is to vasodilate with exercise. And so, if patients had retained that response, the ability to do that, that they may benefit. And so, we sought to figure that out with this subgroup analysis. Dr. Greg Hundley: Sanjiv, it sounds like a really elegant, well thought out hypothesis. So what was your study design? And describe your study population. Dr. Sanjiv Shah: Yeah. This was a randomized controlled trial. And so this was 626 patients enrolled at 89 centers across the world. And it was really, heart failure with mildly reduced, so an EF of greater than 40, or preserved EF, and 93% of them had HFpEF. And what was unique about this trial is that we, this is the first trial really, that confirmed that these patients actually had heart failure, with mildly reduced or preserved ejection fraction. Most trials say, well, you have to have an elevated BNP, and you have to have some sign of structural heart disease, and maybe, a history of heart failure hospitalization. In this trial, every single patient had to undergo rigorous noninvasive echocardiography. And then, on top of that, they had to undergo exercise invasive hemodynamic testing. And people thought that it wasn't possible for 626 patients, but we did it. And every single patient had had an exercise pulmonary capillary wedge pressure greater than, or equal to, 25. And so this really was HFpEF. So it's a randomized trial. Dr. Sanjiv Shah: And then, beyond that, we did a subgroup analysis. So we looked on various subgroups, focusing on exercise PVR, and we really looked to see the effect on three outcomes. Number one, a hierarchical endpoint, a combination of cardiovascular death, ischemic nonfatal stroke, recurrent heart failure hospitalizations, and the KCCQ. And then the other two outcomes were just the individual recurrent heart failure hospitalizations, and the KCCQ. We looked at all of these, and tried to figure out if there are certain subgroups that benefit. Dr. Greg Hundley: Great detail. So Sanjiv, what did you find? Dr. Sanjiv Shah: Well, we found that, there's this group of patients, that during exercise, the pulmonary vascular resistance at peak exercise stays above 1.74 Wood units. Now that seems like an arbitrary number, but in fact, in older individuals that are healthy, when you exercise them, the PVR upper limit, the exercise PVR upper limit, is about 1.8. So we're right about the upper limit of where the PVR should be. And if it was above that, the patients actually did worse with the shunt device. They had a lot more heart failure hospitalizations. Their KCCQ got worse, didn't benefit. And if they were below that threshold, meaning they were, sort of compliant pulmonary vasculature, and it stayed compliant, or they vasodilated effectively with exercise, then they benefited from the device. And what we call this concept of exercise-induced pulmonary vasoconstriction, or inability to vasodilate, is latent pulmonary vascular disease. Dr. Sanjiv Shah: And so, if you have that latent pulmonary vascular disease, your win ratio is 0.6. That means you do worse. And if you don't have this pulmonary, this latent pulmonary vascular disease, your win ratio is 1.31. And that means, you do better with the device. And we saw very similar findings with the KCCQ. We saw similar findings with the recurrent heart failure hospitalizations. Dr. Sanjiv Shah: And the final thing is, we found that, we looked at various other subgroups, and it turned out that if there was no latent pulmonary vascular disease and no history of pacemaker, which we found was kind of associated with sex and right atrial volume, those patients, for about 50% of the group, actually did the best. And that was what we called, the responder subgroup. Dr. Greg Hundley: Thank you, Sanjiv. Well, listeners, we're going to turn now to our associate editor, Justin Ezekowitz. And Justin, you have many papers come across your desk. What attracted you to this particular manuscript? Dr. Justin Ezekowitz: So Greg, this paper kind of stood out for a number of different reasons, as I sent you. You're to be congratulated for a variety of reasons. But the number one is, pursuing the data from a neutral trial overall, to understand who might benefit and who might be harmed from a pretty novel device and way to treat patients in such a scale, that's not being done like this before. So it stands out by just the magnitude of number of right heart catheterizations, number of patients enrolled, number of procedures done. And all of those things really lead to us to be able to understand the area much better than I think we can in a human population. Dr. Justin Ezekowitz: Where this sits with other devices that are very similar, is hard to really know, if all devices are going to be the same or different, but your population is quite unique is if they're not all end stage, but they're sick enough to get into your trials. So there's this population we treat actively. And I wondered if you could touch on that continuous nature. And so for readers, there's this beautiful figure, which shows a continuous nature of exercise PVR. And I wonder if you could touch on that. Is this mid group, the group that we should target for our future therapies like this, or this needs further study? Dr. Sanjiv Shah: Well, I think it needs further study. I think the listeners should be aware that this is a post hoc analysis. We did pre-specify exercise PA pressure. This is one trial. But it makes a lot of sense, pathophysiologically. What we're doing here is we're shunting this excessive LA, overloaded LA, shunting the blood from the LA to the RA and into the pulmonary vasculature. Well, if that pulmonary vasculature can't accept that increased flow, the patient's not going to do well. And how can we simulate that? Well, we can simulate it with exercise. As the patient's pedaling on the bike, on the cath lab table, there's increasing blood flow to the pulmonary vasculature, and we're seeing what happens with the pulmonary vasculature. Does it vasodilate, does it not? And so, I think that's why we were excited about this finding. Dr. Sanjiv Shah: I do think that, there are at least seven other companies making shunt devices, interatrial shunt devices or therapies. And I do think, they need to pay attention to this and really look at this. Not all trials are doing exercise and basic hemodynamics, that needs to be done, I think. So it'll be really interesting to see. Dr. Sanjiv Shah: Now, one thing I will say is that, and I've written about this, this is a really interesting trial. Because the BNPs were lower, and so you would think, okay, these are patients that are less sick. And yet, their heart failure hospitalization rate was at least one and a half times higher than pharma Phase III trials. KCCQ was way lower, like 30 points lower. So there are these patients out there that are really sick, and they're the ones that I think, are where their life, their sort of quality of life, their outcomes, are being driven by the HFpEF. And that's what we found in this trial. Dr. Greg Hundley: Very nice. Well, listeners, let's turn now to our editorialist, Dr. Evangelos Michelakis. And Evangelos, two questions. How do we put the results of this substudy, really in the context of the main trial? And then secondly, do you have any, with your expertise in endothelial function, and understanding the mechanisms of pulmonary hypertension, can you describe what you think might be operative as a mechanism here, and why Sanjiv observed these positive results in some patients? Dr. Evangelos Michelakis: Thank you. So the first point is that, I have to also repeat, that it was a remarkable achievement to do all this right heart catheterization on a treadmill in the cath lab. It's a very complex procedure. And it is, they have to be congratulated, the authors, for actually doing this. There is no question that, like Sanjiv said, ongoing trials for future trials will need to include the hemodynamics in the trials, before and after the procedure. Dr. Evangelos Michelakis: So another important thing is that, the authors brought up this, they called it latent pulmonary hypertension, we could call it latent pulmonary hypertension, or probably, early pulmonary hypertension, as an entity. Now that entity, it's newer in the heart failure field. It's not that old in the PIH, the pulmonary interior hypertension field, since it used to be in the guidelines for this disease, that exercise pulmonary hypertension was a diagnostic criterion for that. Because the idea is that, exercise pulmonary hypertension reflects early pulmonary hypertension. So you needed to intervene with therapies early. Dr. Evangelos Michelakis: Now, I'm not sure that this is a fact. But it is very likely that these patients, in Sanjiv's trial, that had the early, that had the sort of enhanced response with exercise, did have at least, endothelial dysfunction in the pulmonary arteries. Not only because this population has a number of endothelial risk factors, diabetes, smoking, you name it. But also, there are newer problems like SNPs polymorphism mutations, that will recognize more into the pulmonary arterial hypertension field, to be more unique to the pulmonary circulation. Dr. Evangelos Michelakis: But the reason I say that is that, the reason that you dilate with exercise, is mostly because of your pulmonary arterial endothelial cells, secreting vasodilatory factors. And also, allowing previously closed capillaries to open up with increased flow. However, the problem is that, if you have pulmonary arterial endothelial cells in vitro, and you expose them to high flow, like in this case, you can actually change their identity. Turn them into cells that are not endothelial cells anymore, are proliferative pro-inflammatory, and they can actually cause structural pulmonary circulation damage. Dr. Evangelos Michelakis: Also, there are animal models and people working in PAH and ASD, where they've shown that, if you have, if you're given endothelial toxin in animals, and then, you do an aortocaval shunt, then you get really severe pulmonary hypertension with structural disease, that is not even reversible if you remove the shunt. Dr. Evangelos Michelakis: So from this trial, the conclusion that patients with pulmonary hypertension should not get the device, is very clear. And probably, the ones with exercise pulmonary hypertension. My theoretical concern is, for those that don't have exercise pulmonary hypertension, or those that do have it, could they get worse after a number of years, and have structural pulmonary vascular disease? And unfortunately, we didn't have a follow up right heart catheterization to prove that, whether this is right or wrong. Which is a thing, is the most important thing to do in the future. So mimic the protocol for this trial from now on, but also add a follow up right heart catheterization, perhaps not just in a year, but longer. In other words, enough time to allow the structural pulmonary remodeling get established, but also, affect the right ventricle, these things don't. So maybe in a few years. It's a very demanding thing for these protocols, but I think, that's what needs to be done before we say this device can actually be beneficial for those patients, or for some patients, or not hurt others. Dr. Greg Hundley: Very nice. And so, a great segue, Evangelos, into what we think the next studies may need to be performed in this particular sphere of research. Dr. Greg Hundley: So Sanjiv, in just 30 seconds, could you share your thoughts first, and then we'll circulate back to Justin, and then finish up with Evangelos. Sanjiv? Dr. Sanjiv Shah: Yeah. I think the key thing is, to do a confirmatory trial. And that's what we're aiming for, is to do a confirmatory randomized sham-controlled trial, but focus in on these patients with an exercise peak PVR of less than 1.75, around there. And I think, that'll help answer the question. The Qp/Qs we get with this device is 1.2 to 1.3. So I don't think it's a high flow. And we actually have open label studies, where we've gone out to three years, with repeat invasive hemodynamic testing, echocardiograms, and we've had patients who've been implanted for seven years. We're not seeing, at least at that point, any sort of worsening of pulmonary vascular disease, or RV function, or anything like that. And so, it remains to be seen. Dr. Sanjiv Shah: The last thing I'll say, which I think is provocative, in the field of HFpEF, all pulmonary vasodilator drugs have failed. And though, we only measure pulmonary vascular resistance at rest. And what we saw in this trial, is that some patients have a high PVR and it comes down. Some people have a PVR that stays low, and is low and stays low. Some people have a low PVR and it goes up. You know? So I think what we need to think about in the field of PH‐HFpEF, is more exercise genotyping, to determine what's the dynamic exercise PVR? And maybe, those with exercise elevation of pulmonary vascular resistance are the ones that respond to pulmonary vasodilators. So that's another thing that I think we can think about taking away from this trial. Dr. Greg Hundley: Thank you, Sanjiv. Justin. Dr. Justin Ezekowitz: Yeah. So my thoughts are mimicking Sanjiv's. But one of the things that we desperately need is, ways in which we can noninvasively assess the exercise PVR, so that we can think about the large scale interventions that might come down the road, if interventions such as this work well. Because the noninvasive scans will really help us look at broader populations. Those are, that don't make it into trials, and those that aren't traditionally in our studies of HFpEF. So I think, that's another area where we can really grow the field, and then, grow our knowledge. Dr. Greg Hundley: Very nice. And Evangelos. Dr. Evangelos Michelakis: So, yes. Of course, like everybody said, we need trials that will have a follow up right heart catheterization, at least address, if not both, like the investigators did. But because the big question is, are these patients having an earlier stage pulmonary hypertension or not? These patients that the authors called, latent pulmonary hypertension, we need to phenotype more their endothelial cells, or their disease. And in the absence of biopsies, the only way we could do that, is perhaps, with molecular imaging, or at least, in some small populations. Or with analyzing pulmonary arterial endothelial cells in the blood, and their molecular phenotype, to see if they are a distinct group, which I suspect they may be. So further genotyping of this exercise induced pulmonary hypertension in this population, will be important as well. Dr. Greg Hundley: Thank you. Well, listeners, we've had a great discussion today, from Dr. Sanjiv Shah, from Northwestern University in Chicago, our editorialist, Dr. Evangelos Michelakis, from Edmonton, Alberta, and our own associate editor, Dr. Justin Ezekowitz from Edmonton, who brought us this study, demonstrating that in patients with heart failure and preserved ejection fraction, or heart failure and mildly reduced ejection fraction, the presence of pulmonary vascular disease, uncovered by invasive hemodynamic exercise testing, identifies patients who may worsen with atrial shunt therapy. Whereas, those without pulmonary vascular disease may, at least in the short term, benefit. And of course, as Evangelos has pointed out, the long term findings really warrant further study. Dr. Greg Hundley: Well listeners, on behalf of Carolyn and myself, we want to wish you a great week, and we will catch you next week on the Run. Dr. Greg Hundley: This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors, or of the American Heart Association. For more, please visit ahajournals.org.
We talk with Dr. Luke Wilkins about his stenting algorithm for treating peripheral artery disease, including a step by step discussion of the decision tree when deciding whether or not to stent. --- CHECK OUT OUR SPONSOR Boston Scientific Eluvia Drug-Eluting Stent https://www.bostonscientific.com/en-US/medical-specialties/vascular-surgery/drug-eluting-therapies/eluvia/eluvia-clinical-trials.html?utm_source=oth_site&utm_medium=native&utm_campaign=pi-at-us-de_portfolio-hci&utm_content=n-backtable-n-backtable_site_eluvia_1&cid=n10008043 --- SHOW NOTES In this episode, our host Dr. Aparna Baheti interviews interventional radiologist Dr. Luke Wilkins about his treatment algorithm for Peripheral Arterial Disease (PAD). This algorithm is linked below, under “Resources.” Dr. Wilkins starts by explaining his treatment decisions for non-occlusive lesions. If the lesion is less than 10 cm he prefers to use directional atherectomy and percutaneous transluminal angioplasty (PTA). However, if the lesion is greater than 10 cm, directional atherectomy poses the risk of distal embolization, so he will only perform PTA. In both cases, he recommends using IVUS to evaluate the efficacy of the treatment and then proceeding with a drug-coated balloon (DCB) to prevent re-stenosis. On the other hand, if the disease is occlusive, Dr. Wilkins first attempts to cross the lesion. This can be achieved by going through microchannels with a guidewire or boring through the occlusion with a crossing device. If the lesion is unable to be crossed, he attempts subintimal recanalization. We discuss spontaneous re-entry into the true lumen, as well as re-entry devices like the Outback and the Pioneer catheters. We also take a detour into the Subintimal Arterial Flossing with Anterograde-Retrograde Intervention (SAFARI) technique that can be used if re-entry is challenging. After crossing is complete, Dr. Wilkins evaluates vessel diameter. In his experience, vessels that are wider than 5 mm have better stent patency, so he will place a drug eluting stent. In vessels of smaller diameters, Dr. Wilkins relies on other approaches such as interwoven stents with smaller diameters, directional atherectomy, and Tacks (to treat dissection flaps). Finally, Dr. Wilkins discusses medical management and follow-up care for PAD patients. He recommends dual antiplatelet therapy, smoking cessation, and if claudication was an initial concern, patient education on the importance of walking. He follows up with patients in 1, 6, and 9 months, and then annually. During each follow up appointment, he checks ABI, PVR, and arterial duplex for clinical improvement. --- RESOURCES PAD Stenting Algorithm Decision Tree: https://www.backtable.com/shows/vi/podcasts/200/pad-stenting-algorithm TASC Guidelines: https://journals.sagepub.com/doi/10.1177/1358863X15597877?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Articles Mentioned: Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, Micari A, Shishehbor MH, Tepe G, Zeller T. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. Journal of the American College of Cardiology. 2019 May 28;73(20):2550-63. Secemsky EA, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, Beckman JA, Mustapha J, Rosenfield K, Yeh RW. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA cardiology. 2019 Apr 1;4(4):332-40. Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, Faldum A, Reinecke H. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. European heart journal. 2020 Oct 7;41(38):3732-9.
Hello dear #TranceFamily, welcome to Uplifting Trance Sessions EP. 568. I am DJ Phalanx and in this episode you will hear fresh new music by Dash Berlin, Robbie Seed, Talle 2XLC, & DJ T.H., Steve Allen, Angelus, PVR, Gayax & Victor Special and many more. Join the show and enjoy the trip
Hello dear #TranceFamily, welcome to Uplifting Trance Sessions EP. 568. I am DJ Phalanx and in this episode you will hear fresh new music by Dash Berlin, Robbie Seed, Talle 2XLC, & DJ T.H., Steve Allen, Angelus, PVR, Gayax & Victor Special and many more. Join the show and enjoy the trip
Hello dear #TranceFamily, welcome to Uplifting Trance Sessions EP. 568. I am DJ Phalanx and in this episode you will hear fresh new music by Dash Berlin, Robbie Seed, Talle 2XLC, & DJ T.H., Steve Allen, Angelus, PVR, Gayax & Victor Special and many more. Join the show and enjoy the trip
Instagram: zacshomler . PATREON: https://www.patreon.com/zacshomler . PayPal: paypal.me/zacshomler . For business inquiries: sshomler@sparktobonfire.com . iTunes https://itunes.apple.com/us/podcast/strongopinionsports/id1276993522?mt=2 . Spotify: https://open.spotify.com/show/6P9sn1XNNX79Jrb9n2iDag . SoundCloud: https://soundcloud.com/strongopinionsports . YouTube: https://www.youtube.com/channel/UCN0jY4_se9VmRJLFne3OrBA . 0:00 Start 1:13 No NFL Preseason Games 16:22 QB Bubble Will Burst 22:37 Washington Football Team 24:43 Washington Sentinels? 27:21 Can We Be Honest About Lebron Getting Snubbed 35:37 Blazers Are My NBA Dark Horse 39:24 Lakers Are My NBA Favorite 45:40 Seattle Kraken Were Announced 48:33 Mike Tyson Will Fight Again (at 54) 51:09 Lessons I Learned Playing Football Pt 2 57:06 Taking A Few Days Off 1:00:21 #ShortSeasonMLB2012 1:06:59 Predictions vs Reality: NFC West 1:08:06 49ers PvR 1:12:13 Seahawks PvR 1:14:26 Cardinals PvR 1:15:34 Rams PvR
© 2020-2025 Ivy Podcast Discovery LLC
